ÖZET
Şiddetli akut solunum yolu enfeksiyonu sendromu-koronavirüs-2 (SARS-CoV-2) genomu, lipit çift tabakası ile çevrelenen sarmal bir nükleokap-sid içine paketlenmiştir. Virüs zarfı, spike proteini (S), zar proteini (M) ve zarf proteini (E) olarak isimlendirilen en az üç viral protein içermek-tedir. M ve E virüsün yapısını oluştururken, S proteini virüslerin konakçıya girişinin önde gelen aracısıdır. Anjiyotensin dönüştürücü enzim-2 (ACE-2), SARS-CoV ve SARS-CoV-2 dahil koronavirüsler için fonksiyonel bir reseptör olarak tanımlanmıştır. Viral füzyon SARS-CoV-2 enfeksiyo-nunun başlangıcında temel adımı oluşturmaktadır. Spike protein ve ACE-2 füzyonunu engelleyen ilaçların, renin-anjiyotensin-aldesteron sis-temi üzerine etki eden ilaçların ve ekses dozda ACE-2’nin bu füzyon mekanizması üzerine etki ederek COVİD-19 tedaviside yer alabileceği düşünülmüştür. Bu bağlamda özellikle nano-boyutlu lipozomal taşıyıcılar, enfeksiyöz hastalıkların tedavisinde biyo-uyumlulukları ve hücreye benzer yapıları nedeniyle dikkat çekmektedir. Lipozomların geleneksel anti-enfektif ilaçları desteklemek için ikincil bir terapötik olarak da kullanıldığı çalışmalar bulunmaktadır. Bu derlemede virüslerin ACE-2 aracılı girişini engelleyerek hastalığın şiddetini azaltma ve tedavi etme ihtimali olan terapötik yaklaşımlar ele alınmıştır.
References
1
Akbabaa M, Kurtb B, Nazlıcanc E. A New Coronavirus Outbreak: MERS-CoV. Turk J Public Health 2014;12:217-27.
2
KLİMUD. Yeni Koronavirüs (‘’Novel Coronavirus’’ 2019-nCoV) - KLİMUD Klinik Viroloji Çalışma Grubu Bilgi Notu 2020. Available from: https://www.klimud.org/content/779/yeni-koronavirus-novel-coronavirus-2019-ncov---klimud-klinik-viroloji-calisma-grubu-bilgi-notu-.
3
Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60.
4
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Statpearls: StatPearls Publishing; 2020.
5
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315-31.
6
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012;4:1011-33.
7
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother 2020;16:1232-8.
8
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90.
9
FIP. COVID-19: Klinik Bilgi ve Tedavi Kılavuzları. 2020. Available from: https://www.fip.org/file/4825
10
Belete TM. A review on Promising vaccine development progress for COVID-19 disease. Vacunas. Amsterdam: Elseiver; 2020.
11
Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;382:1653-9.
12
Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med 2020;18:1-3.
13
Shih H-I, Wu C-J, Tu Y-F, Chi C-Y. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 2020;43:351-4.
14
Ni L, Zhu J, Zhang J, Yan M, Gao GF, Tien P. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. Biochem Biophys Res Commun 2005;330:39-45.
15
Sempowski GD, Saunders KO, Acharya P, Wiehe KJ, Haynes BF. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell 2020;181:1458-63.
16
Wu Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Virol Sin 2020;35:256-8.
17
Saavedra JM. Angiotensin receptor blockers and COVID-19. Pharmacol Res 2020;156:104832. doi: 10.1016/j.phrs.2020.104832. PubMed PMID: 32304747; PubMed Central PMCID: PMCPMC7158830.
18
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 2005;11:875-9.
19
Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013;52:783-92.
20
Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care 2017;21:1-9.
21
Yimin L. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 2020. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04287686.
22
Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep 2012;64:1020-37.
23
Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. Science 2004;303:1818-22.
24
Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009;137:104-9.
25
Rao L, Tian R, Chen X. Cell-membrane-mimicking nanodecoys against infectious diseases. ACS Nano 2020;14:2569-74.
26
Hendricks GL, Velazquez L, Pham S, Qaisar N, Delaney JC, Viswanathan K, et al. Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res 2015;116:34-44.
27
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013;8:102.
28
Mansoori Agrawal MA, Jawade S, Khan S, M I. A review on liposome. Int J Adv Res Pharm Bio Sci 2012;2:453.
29
Bangham A, Standish M, Weissmann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 1965;13:253-IN28.
30
Serrano G, Kochergina I, Albors A, Diaz E, Oroval M, Hueso G, et al. Liposomal lactoferrin as potential preventative and cure for COVID-19. Int J Res Health Sci 2020;8:8-15.
31
Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design. Curr Pharm Des 2017;23:362-72.
32
Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J Control Release 1993;24:209-23.
33
Tüylek Z. İlaç Taşıyıcı Nanosistemler. Arşiv Kaynak Tarama Derg 28:184-92.
34
Wei Y, Zhao L. Passive lung-targeted drug delivery systems via intravenous administration. Pharm Dev Technol 2014;19:129-36.
